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Novelty and impact 
The constitutional translocation between chromosome bands 11q23 and 22 q11 is recurrent in 
human populations, with highly consistent breakpoints. In this first long-term follow-up study 
of site-specific cancer and mortality risks among carriers, an increased risk of breast cancer 
was observed, with greatest risks in younger women. The results suggest carriers may require 
enhanced surveillance for breast cancer and point to the importance of the chromosomal 
regions 11q23 and 22q11 in breast cancer development. 
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Abstract 
The constitutional t(11;22)(q23;q11) translocation is the only recurrent non-Robertsonian 
translocation known in humans. Carriers are phenotypically normal and are usually referred 
for cytogenetic testing because of multiple miscarriages, infertility, or having aneuploidy in 
offspring. A breast cancer predisposition has been suggested, but previous studies have been 
small and had methodological shortcomings. We therefore conducted a long-term prospective 
study of cancer and mortality risk in carriers.  
We followed 65 male and 101 female carriers of t(11;22)(q23;q11) diagnosed in cytogenetic 
laboratories in Britain during 1976-2005 for cancer and deaths for an average of 21.4 years 
per subject. Standardised mortality (SMR) and incidence (SIR) ratios were calculated 
comparing the numbers of observed events with those expected from national age-, sex-, 
country- and calendar-period-specific population rates. 
Cancer incidence was borderline significantly raised for cancer overall (SIR=1.56, 95% CI: 
0.98-2.36, n=22), and significantly raised for invasive breast cancer (SIR=2.74, 95% CI: 
1.18-5.40, n=8) and in situ breast cancer (SIR=13.0, 95% CI: 3.55-33.4, n=4). Breast cancer 
risks were particularly increased at ages <50 (SIR=4.37, 95% CI: 1.42-10.2 for invasive, 
SIR=22.8, 95% CI: 2.76-82.5 for in situ). Mortality was borderline significantly raised for 
breast cancer (SMR=4.82, 95% CI: 0.99-14.1) but not significantly raised for other cancers or 
causes.   
Individuals diagnosed with t(11;22)(q23;q11) appear to be at several-fold increased breast 
cancer risk, with the greatest risks at premenopausal ages. Further research is required to 
understand the genetic mechanism involving 11q23 and 22q11 and there may be a need for 
enhanced breast cancer surveillance among female carriers.  
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Introduction 
The constitutional t(11;22)(q23;q11) translocation is the only recurrent non-Robertsonian 
translocation known in humans, with highly consistent breakpoints 
1, 2
. Carriers are 
phenotypically normal and are usually diagnosed as a result of investigation for multiple 
miscarriages, infertility, or after having offspring with Emanuel syndrome (supernumeracy 
derivative 22 syndrome).  
Investigation of mortality and cancer risks in t(11;22) carriers is important for counselling of 
carriers and can additionally provide insights into our understanding of cancer aetiology. A 
predisposition to breast cancer among female carriers has been suggested based on the 
presence of subjects with a history of breast cancer among relatively small clinical series of 
carriers 
3-6
, although a recent pedigree study did not observe an excess of cases 
7
. Such 
studies have several potential methodological shortcomings including biased selection of 
carriers, dependence on recall of historical breast cancer diagnoses in relatives by a proband, 
and lack of detail on relatives to compute the expected numbers of cases. 
A prospective investigation, in which subjects diagnosed with the translocation are followed 
up over time for subsequent cancer risk would avoid these potential biases. However, there 
are no such prospective studies except for one very small investigation including 16 carriers 
8
. We therefore conducted a long-term prospective follow-up study of carriers diagnosed 
across Britain and analysed site-specific cancer incidence and cause-specific mortality. 
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Methods 
We collected information on carriers diagnosed postnatally with t(11;22)(q23;q11) from all 
but one cytogenetic centres in Britain between 1976-2005 (exact years varied by centre). 
Carriers whose records indicated they had been ascertained because of cancer were excluded. 
Information on subjects was matched to the National Health Service Central Registers 
(NHSCRs) for England and Wales and Scotland, which provided information on deaths, 
emigrations and other exits from the NHS, and are effectively population registers for these 
countries. Permission for this study was obtained from appropriate ethics committees in the 
UK and the national personal information advisory group. 
Follow-up for cancer and mortality risk started at cytogenetic diagnosis and ended on the 
latest date event notifications were thought to be complete (31 December 2015 for incidence, 
31 December 2016 for mortality), the patient’s 85th birthday, date of death or date of other 
loss to follow-up, whichever was earliest. The observed numbers of deaths and cancers since 
cytogenetic diagnosis were compared against the expected number of cases based on age-, 
sex-, country- and calendar-year specific mortality and incidence rates from the general 
population. We computed standardised mortality (SMR) and incidence (SIR) ratios and their 
95% confidence intervals (CIs) using exact methods 
9
. Where zero cases were observed, the 
upper bound of the confidence interval reflected the 97.5% distribution to make the boundary 
comparable to those of estimates with non-zero observations. We calculated absolute excess 
rates (AERs) by subtracting the expected from the observed numbers of deaths, dividing by 
person-years at risk and multiplying by 100,000. We analysed neoplasms classified as 
malignant according to the ICD 9
th
 revision 
10
 except that we additionally analysed in situ 
breast cancer and that analyses of nervous system tumours included non-malignant 
registrations. Analyses were conducted for all subjects combined and, for breast cancer 
outcomes, by attained age <50, 50 years as a proxy for menopausal status in females. In 
order to investigate the possibility that mortality or cancer incidence might have been biased 
because some subjects were cytogenetically tested as a consequence of a prior illness, 
analyses were repeated after excluding from follow-up the first 36 months after cytogenetic 
diagnosis. 
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Results  
We ascertained 217 subjects diagnosed with t(11;22)(q23;q11) at the study centres, 170 of 
whom could be matched on the NHSCRs because sufficient details were available. After 
excluding 4 subjects referred for testing because of cancer, the cohort study consisted of 166 
individuals (65 males and 101 females) (Table 1). They were diagnosed at a median age of 
30.9 years (range 0-84.8 years). Median follow-up was 21.4 years per subject for mortality 
and 20.4 years for incidence.  
During follow-up, 20 subjects died, 134 were followed-up to the end of the study or age 85, 
and 12 emigrated or exited in other ways. There were 22 incident malignancies recorded 
during follow-up, a borderline significantly greater number than expected from national rates 
(SIR=1.56, 95% CI: 0.98-2.36) (Table 2). There were 8 invasive and 4 in situ diagnoses of 
breast cancer in 10 subjects aged 38-82 years. Diagnoses in the two subjects with multiple 
registrations were at least four years apart.  Incidence was significantly raised for invasive 
(SIR=2.74, 95% CI: 1.18-5.40, AER=155, i.e. 155 additional cases per 100,000 population 
per annum) and in situ (SIR=13.0, 95% CI: 3.55-33.4, AER=112.9) breast cancer, with all 
cases occurring in females. Risk of breast cancer was more greatly raised at younger ages. 
For invasive breast cancer, the SIR was 4.37 (95% CI: 1.42-10.2) at ages <50 and 1.69 (95% 
CI: 0.35-4.93) at ages 50 years (Table 3).  Two of the invasive cases were diagnosed under 
age 40 years (SIR=7.58, 95% CI: 0.92-27.4) (not in table). For in situ breast cancer at ages 
<50 years, the SIR was 22.8 (95% CI: 2.76-82.5) and risk was also significantly raised at 
older ages (SIR=9.12, 95% CI: 1.10-33.0).  
All of the incident cancers were diagnosed at least three years after cytogenetic diagnosis and 
excluding the first three years of follow-up after cytogenetic diagnosis led to slightly stronger 
SIRs (SIR=1.70, 95% CI: 1.07-2.57 for all malignancies and SIR: 2.95, 95% CI: 1.27-5.81 
for invasive breast cancer, not in table). SIRs for other sites were not significantly raised or 
reduced, but the numbers of cases were small (Table 2). There were 4 cases of lung cancer, 2 
cases of corpus uteri cancer and single cases at other sites.  The 2 malignancies of the corpus 
uteri were both endometrioid. 
We did not collect information on pedigrees but based on cytogenetic centre and patient 
details we ascertained that our study population included at least 64 individuals with one or 
more relatives in the study, from 22 families. All malignancies, including the ten breast 
cancer cases, arose in subjects from independent families.  
7 
 
Cancer mortality overall was not significantly raised in comparison with the general 
population expectation (SMR=1.44, 95% CI: 0.66-2.74, n=9 deaths), and was borderline 
significantly raised for invasive breast cancer (SMR=4.82, 95% CI: 0.99-14.1, n=3 deaths), 
but not for other cancer-sites. The SMR for all malignancies except breast cancer was 1.07 
(95% CI: 0.39-2.33).  Two of the deaths from breast cancer were among women aged <50 
(SMR=11.0, 95% CI: 1.34-39.9, not in table). After excluding the first three years after 
cytogenetic diagnosis from the analysis, the SMR for breast cancer at all ages was 5.34 (95% 
CI: 1.10-15.6). Mortality from other causes than cancer was not raised (Table 4). 
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Discussion 
We observed that carriers were at several-fold greater risk of breast cancer than the general 
population, with the greatest risk increases among young women, but there was no substantial 
evidence of a raised risk for other cancers. The associations were stronger when we only 
considered follow-up more than three years after cytogenetic diagnosis, therefore making it 
highly unlikely that the findings are due to referral because of a pending cancer diagnosis. 
The only previous prospective investigation of cancer risk in carriers observed that, among 16 
carriers of t(11;22)(q23:q11), one of the two subjects who developed cancer during follow-up 
had breast cancer, but this did not reach statistical significance (SIR=2.63, 95% CI: 0.30-
9.50) 
8
.  
It is unclear why the relative risk increases were greater for in situ than invasive breast 
cancer. A greater proportion of in situ than invasive tumours are first detected by 
mammographic screening, and in situ cancers represent a greater proportion of screen-
detected cancers  among women screened at ages <50 years than older ages
11
. If the raised 
risk of breast cancer is causal, we might expect carriers to be more likely to have a family 
history of breast cancer than the general population. It is possible therefore that risks of in 
situ breast cancer are somewhat inflated because carriers are invited for enhanced breast 
cancer screening due to their family history.  
 
Previous reports of a breast cancer predisposition in t(11;22) carriers have been based on 
identification of individuals with a history of breast cancer in pedigree studies or case series 
of carriers 
3-7
. Some of the studies have had contradictory results, however. Lindblom et al 
observed four cases of breast cancer among 16 female carriers identified from eight pedigree 
families, which they estimated constituted a 10-fold increased risk
3
. However, the largest 
pedigree study to date, by Carter et al, did not observe an excess of breast cancer cases 
among 103 female carriers from 80 pedigrees ascertained for reproductive-related reasons 
7
. 
Information on carrier status and breast cancer in relatives was initially obtained from a 
proband carrier in each family and such dependence on recall by the proband is a possible 
cause of bias. Some past studies are also prone to ascertainment bias if a subject or family is 
recruited into the investigation due to their cancer history or is referred for cytogenetic testing 
because of a cancer diagnosis. Furthermore, in past studies it is difficult to establish whether 
there is an excess of cases given that the expected number in the reference population 
depends on the number of relatives, their ages and calendar periods of follow-up. Our study 
9 
 
design overcomes such weaknesses due to its longitudinal design, computation of expected 
rates, national follow-up and use of routine collected cancer registrations.  
The observed raised risks of breast cancer, in particular among younger women, point to 
importance of the 11q23 and 22q11 regions in breast cancer development. Two common 
regions of loss of heterozygosity have been identified in the region 11q23 in breast cancer 
12-
14
. The region 22q11.2 is known to be susceptible to rearrangements 
15
 and both breakpoints 
in t(11;22) carriers have been mapped outside gene coding regions to similar palindromic 
AT-rich repeats (PATRRs) 
1, 2, 6
. Intrastrand base-pairing of AT-rich palindromes can lead to 
formation of hairpin and cruciform structures that promote double strand breaks and 
illegitimate recombination between homologous regions on distinct chromosomes such as the 
11q23 and 22q11 sites. The increased risk of breast cancer may result from a consequent 
‘position effect’ of the translocation on the expression of a neighbouring breast cancer 
susceptibility gene(s) 
16
. The 22q11.2 cannot be unambiguously assigned within a large 424 
kb region; but the 11q23.3 breakpoint has been mapped to a region approximately 9kb from 
APOA4 
2
, within a cluster of apolipoprotein genes. While there is no known association 
between APOA4 and breast cancer risk, two plausible candidates (ZNF259 and BUD13) map 
approximately 42kb and 57kb centromeric to the 11q23.3 breakpoint. Alternatively, loss of 
the small der(22) chromosome by nondisjunction during meiosis could also result in loss of a 
tumour suppressor gene copy (similar to the 11q23 loss-of-heterozygosity observed in breast 
cancer) leading to a breast cancer disposition 
6
. 
  
The number of calendar years for which we extracted records varied by centre depending on 
the years the centre was operational, availability of historical records and the calendar period 
of extraction. The availability of records for operational reasons is unlikely to have caused 
bias in the results. However, most carriers are not detected unless they get referred for 
cytogenetic testing for experiencing reproductive problems or abnormalities in offspring. Our 
study is therefore of patients with t(11;22) who are eventually diagnosed, but from a clinical 
and counselling perspective this is the group of carriers of relevance. It is possible that the 
raised risks of breast cancer are related to the selective forces that lead to cytogenetic 
diagnosis of carriers: for instance  if women who get referred for cytogenetic testing are of 
higher socioeconomic status than those who are not referred (breast cancer rates being greater 
in higher socioeconomic strata
17
). Additionally, carriers might have fertility problems, and 
nulliparity and delayed childbirth are risk factors for breast cancer 
18
. The latter is somewhat 
10 
 
supported by the finding that risk of endometrial cancer, which is associated with nulliparity 
and infertility 
19
, was non-significantly raised in this cohort, based on two cases. These 
factors are not expected to increase breast cancer risk more than twofold, however, and 
therefore do not explain the raised risks in full. We did not have information on whether 
individuals had also been tested for BRCA1 or BRCA2 mutations, but the prevalence of these 
mutations is low, ~2% in unselected patients diagnosed age 35 and over 
20
, and we are not 
aware of such mutations being more common in t(11;22) carriers. It therefore seems unlikely 
that the presence of BRCA1/BRCA2 mutations is the reason for the raised breast cancer risks 
observed in this cohort. 
 
The translocation t(11;22)(q23;q11) represents 1.2% of all diagnosed reciprocal 
translocations
8
, the latter having a frequency of  0.5-2.7 per 1000 in the population 
21, 22
. 
Given the frequency of the translocation in the population, our prospective study comprised a 
relatively large population of carriers. However, a limitation of the study is that the number 
of carriers was still too small to investigate less common types of cancer or associations with 
modest risk increases. Risks of melanoma and oesophageal cancer were not increased among 
carriers, in contrast to the report by Carter et al 
7
; we observed one case of oesophageal 
cancer, but the SIR was not significantly raised. Additionally, we did not collect information 
on subjects’ lifestyle factors and it is possible that the carriers are not representative of the 
general population with respect to other factors.  
In conclusion, individuals diagnosed with t(11;22)(q23;q11) showed increased rates of breast 
cancer compared with the general population, in particular in women aged under 50 years. 
The mechanistic involvement of the breakpoints on 11q23 and 22q11 in breast cancer 
development needs to be investigated and increased breast cancer surveillance in female 
carriers may be warranted. 
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Table 1: Characteristics of 166 subjects cytogenetically diagnosed with t(11;22)(q23;q11) 
during 1976-2005 (varying by cytogenetic centre) in Great Britain 
 
Characteristic No. % 
   
Sex   
Male 65 39.2 
Female 101 60.8 
   
Age at cytogenetic diagnosis (years)   
0-4 6 3.6 
5-14 13 7.8 
15-24 22 13.3 
25-34 65 39.3 
35-44 22 13.3 
45-64 30 18.1 
65-84 8 4.8 
   
Calendar year of cytogenetic diagnosis   
1976-1979 2 1.2 
1980-1989 32 19.3 
1990-1999 125 75.3 
2000-2005 7 4.2 
   
Year of birth   
<1950 43 25.9 
1950-1969 81 48.8 
1970-1989 36 21.7 
1990-2005 6 3.6 
   
Total 166 100.0 
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Table 2:  Cancer incidence and mortality in carriers of t(11;22)(q23;q11) translocations  
   Incidence     Mortality  
ICD-9
 
code Cancer site No. SIR  (95% CI) AER  No. SMR  (95% CI) AER 
         
140-171, 173-208 All malignant neoplasms
a
 22 1.56 (0.98-2.36) 241.0  9 1.44 (0.66-2.74) 81.3 
150 Oesophagus 1 3.18 (0.08-17.7) 20.9  0 0 (0-12.8) -8.5 
153-154 Colon and rectum 1 0.64 (0.02-3.54) -17.5  0 0 (0-6.11) -17.7 
162 Lung 4 2.35 (0.64-6.01) 70.1  3 2.08 (0.43-6.09) 45.9 
163 Pleura 1 11.1 (0.28-62.0) 27.8  0 0 (0-129.4) -0.84 
174-175, 233.0 Breast, invasive or in situ 12 3.72 (1.92-6.49)** 268.2  3 4.82 (0.99-14.1) 70.0 
    174, 175     Breast, invasive 8 2.74 (1.18-5.40)* 155.0  3 4.82 (0.99-14.1) 69.9 
    233.0     Breast, in situ 4 13.0 (3.55-33.4)** 112.9  0 0 (0-∞) 0 
179,182 Corpus uteri 2 5.55 (0.67-20.1) 81.4  0 0 (0-54.6) -3.2 
185 Prostate 1 0.69 (0.02-3.87) -35.0  0 0 (0-13.4) -21.0 
189 Kidney and ureter 1 2.70 (0.07-15.1) 19.2  0 0 (0-24.9) -4.4 
200, 202 Non-Hodgkin lymphoma 1 1.93 (0.05-10.8) 14.7  1 5.41 (0.14-30.1) 24.0 
204-8 Leukaemia 1 3.15 (0.08-17.6) 20.8  0 0 (0-22.3) -4.9 
191, 192, 225, 237.5, 
237.6, 237.9, 239.6 
Nervous system, including 
benign 
0 0 (0-8.91) -12.6  1 4.34 (0.11-24.2) 22.6 
196.0-199.1 Unknown primary site 0 0 (0-8.62) -13.1  1 1.96 (0.05-10.9) 14.4 
16 
 
Abbreviations: AER, absolute excess rate; CI, confidence interval; ICD, International Classification of Diseases, 9
th
 revision 
10
; SIR, standardised incidence ratio; SMR, 
standardised mortality ratio 
*p<0.05    
**p<0.001  
a) The category ‘All malignant neoplasms’ included neoplasms classified as malignant according to the ICD revision 9 10, excluding non-melanoma skin cancer because it is 
under- ascertained by the cancer registries 
23
. Analyses by cancer site included registrations coded to malignant, with the exception that in situ breast cancers and non-
malignant nervous system tumours were included where stated. 1 malignancy of ill-defined site is not listed individually in the table.  
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Table 3:  Breast cancer incidence in carriers of t(11;22)(q23;q11) translocations, by attained age  
   Attained age, years 
   <50    50  
ICD-9
 
code Cancer site No. SIR  (95% CI) AER  No. SIR  (95% CI) AER 
         
174, 175, 233.0 Breast, invasive or in situ 7 5.69 (2.29-11.7)*** 255.5  5 2.50 (0.81-5.84) 296.4 
174, 175 Breast, invasive 5 4.37 (1.42-10.2)* 170.5  3 1.69 (0.35-4.93) 120.6 
2330 Breast, in situ 2 22.8 (2.76-82.5)** 84.7  2 9.12 (1.10-33.0)* 175.8 
         
Abbreviations: AER, absolute excess rate; CI, confidence interval; ICD, International Classification of Diseases, 9
th
 revision 
10
; SIR, standardised incidence ratio 
*p<0.05 
**p<0.01 
***p<0.001 
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Table 4: Cause-specific mortality, by ICD-9 chapter 
10
, in carriers of t(11;22)(q23;q11) 
translocations 
 
ICD-9 
Code 
 
Cause 
No. of 
deaths 
SMR (95% CI) AER 
     
140-208 All malignant neoplasms 9 1.44 (0.66-2.74) 81.3 
240-279 Endocrine, nutritional, metabolic, 
immunity 
1 3.61 (0.09-20.1) 21.3 
290-319 Mental disorders 0 0.0 (0-9.36) -11.6 
320-389 Diseases of the nervous system 0 0.00 (0-6.70) -16.2 
390-459 Diseases of the circulatory system 3 0.56 (0.12-1.63) -69.7 
460-519 Diseases of the respiratory system 5 2.72 (0.88-6.35) 93.0 
520-579 Diseases of the digestive system 2 2.02 (0.24-7.29) 29.6 
580-629 Diseases of the genitourinary system 0 0.00 (0-18.4) -5.9 
710-739 Musculoskeletal system and connective 
tissue 
0 0.00 (0-33.1) -3.3 
740-759 Congenital anomalies 0 0.00 (0-59.7) -1.8 
800-999 Accidents and violence 0 0.00 (0-3.94) -27.5 
001-999 All causes 20 1.14 (0.70-1.77) 74.3 
Abbreviations: AER, absolute excess rate; CI, confidence interval ; ICD, International Classification of Diseases, 
9
th
 revision 
10
; SMR, standardised mortality ratio 
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